CJC-1295 (No DAC) / GHRP-6 Blend
Also known as: CJC-1295 & GHRP-6, CJC-1295 No DAC + GHRP-6 Blend, Mod GRF 1-29 & GHRP-6
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-6, a ghrelin-mimetic secretagogue noted for strong appetite stimulation, to synergistically boost growth hormone release. Both are unapproved research peptides.
Last updated
Mechanism of Action
CJC-1295 without DAC is a modified GHRH(1-29) analog that binds the pituitary GHRH receptor and increases the amplitude of endogenous growth-hormone pulses. GHRP-6 is a synthetic hexapeptide ghrelin mimetic that activates the GHS-R1a receptor to trigger GH release and reduce somatostatin inhibition, and it is the most potent of the GHRPs for stimulating appetite via central ghrelin signaling. Pairing a GHRH analog with GHRP-6 yields a synergistic GH pulse because the two receptor systems reinforce one another. The short half-life of the no-DAC form keeps GH and IGF-1 release pulsatile and physiologic.
- Half-life
- Short for both components: roughly 30 minutes for CJC-1295 no DAC and about 15-30 minutes for GHRP-6
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Synergistic pulsatile growth hormone release
- Marked appetite stimulation (useful in mass-gain models)
- Raises downstream IGF-1 levels
- Studied for recovery, lean mass, and body composition
- Short-acting profile maintains physiologic GH pulses
- Two complementary GH-release pathways combined
Potential Side Effects
- Pronounced hunger shortly after administration
- Injection-site redness or irritation
- Water retention, tingling, or numbness
- Elevated cortisol or prolactin and possible flushing
- Headache or reactive hypoglycemia
Common Dosing
For research use only and not medical advice: research protocols commonly combine roughly 100 mcg CJC-1295 (no DAC) with 100-200 mcg GHRP-6 per subcutaneous administration, often dosed 1-3 times daily on an empty stomach. No validated human dosing exists.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or history of malignancy (GH and IGF-1 elevation)
- Uncontrolled diabetes or significant insulin resistance
- Pregnancy or breastfeeding
CJC-1295 (No DAC) / GHRP-2 Blend
This blend pairs CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-2, a growth hormone secretagogue, to synergistically stimulate pulsatile growth hormone release. Both are unapproved research peptides.
GHRP-6
An early growth hormone releasing peptide best known for strong GH stimulation alongside a pronounced increase in appetite via ghrelin signaling.
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
1990
- View
Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man
1995
- View
Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats
1995